Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

When Do Recurrences of Lung Cancer Happen After Surgery?
Author
Howard (Jack) West, MD

The answer is, "Usually pretty early". I tell my patients that the risk is "front-loaded", meaning that we typically see recurrences occur in the first couple of years after curative therapy for lung cancer, if they're going to happen at all. That said, I haven't seen a lot of data that actually illustrates the point, but there was a presentation at ASCO this past year that addressed how well recurrences/disease-free survival predict overall survival after surgery for resectable NSCLC. Not surprisingly, there was a very good correlation, though it wasn't perfect (patients can die from side effects of the treatment, or from unrelated but competing medical problems).

In the process of reviewing the data from two "meta-analyses" of multiple smaller studies of chemotherapy after surgery, either with or without radiation also administered, a group led by Dr. Michiels from Institute Gustave-Roussy in Villejuif, France reported on the "lead time" that diseease-free survival gives in predicting overall survival. They found that, if recurrences were going to ever happen, about 50% occurred within the first year, at least two-thirds within two years, and about 80% or more within three years.

time-to-recurrence-in-early-stage-nsclc (click on image to enlarge)

This really corroborates the experience of clinicians caring for patients after surgery. Once you get out 2-3 years after surgery, odds are decidedly in your favor, with declining risk of ever seeing a recurrence if it hasn't happened within that time. Though the authors didn't report on the data with greater specificity, I strongly suspect that the data would show that patients with higher stage disease (stages II and III, for instance) are even more likely to recur early or not at all, while those with stage I NSCLC, especially those with smaller tumors or with cancers that we'd anticipate having more indolent behavior (bronchioloalveolar carcinoma, for instance) still having a risk that stretches out for years.

I don't think I've seen a similar analysis of patients with locally advanced NSCLC treated with chemo/radiation, but we see the same trend of front-loaded risk there too. Almost always focusing on patients with a higher stage than resected NSCLC trials, these studies show a median DFS of about 10 months, while others are dropping out from significant side effects and even a 5-7% treatment-related death rate in the more aggressive chemo/radiation trials (and these are in more selected patients than the broader population in the real world, many of whom wouldn't be eligible for such trials). A just-published trial of new non-surgical strategies for stage III NSCLC used OS 18 months after enrollment/start of treatment as the predictor of the efficacy of the strategy.

Clearly, the take-home message is that the risk of recurrence/progression for most patients with potentially curable lung cancer -- and this applies to limited disease small cell lung cancer as well -- is primarily focused in the first 12-24 months, diminishing thereafter. How early the peak risk is, and how long the tail of recurrence risk goes out, is largely related to the aggressiveness of the underlying cancer.

Next Previous link

Previous PostNext Post

Related Content

Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Yang, Das, and Dagogo-Jack discuss commonly used terms in treatment options for lung cancer, how oncologists determine the stage of lung cancer, and what that means for treatment, the importance of driver mutation in NSCLC treatment, the vast number of NSCLC trials, among other topics which involve lung cancer treatments. To watch the complete playlist click here.
Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Jeff Yang, discusses different surgical procedures used to treat early-stage lung cancer and different approaches to removing cancerous tissue from the lung. 
Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Millie Das, discusses different Studies and Trials for NSCLC. Dr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is the Chief of Oncology at the Palo Alto VA and is an active member of the VA National Lung Cancer Working Group and Lung Cancer Precision Oncology Program. Learn more about Dr. Das here.

Forum Discussions

Hi and welcome to Grace.  Wow, I don't know why you can't get in to see your doc but I'd find a way or find another doc who can walk you...

Hi Amber, Welcome to Grace.  I'm so sorry you're going through this scare.  It could be a recurrence.  It also is as likely to be the contrast creating a better view. ...

Hi Blaze,

 

As much as I hate to say it, Welcome back Blaze.  It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...

Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3

It sounds like you’re thinking of this in a very appropriate way. Specifically, it sounds like the growth of the nodule is rather modest, though keep in mind that the change...

Hi and welcome to GRACE.  I'm sorry your mom is having this difficulty.  An indwelling catheter is used when the pleura space continually fills and the catheter is always there to...

Recent Comments

JOIN THE CONVERSATION
 Hi arm2966, Welcome to…
By JanineT GRACE … on
Joanne indwelling catheters
By arm2966 on
Hi and welcome to Grace. …
By JanineT GRACE … on
Hi Amber, Welcome to Grace. …
By JanineT GRACE … on